Radical Prostatectomy

Hammad, Fayez T.

doi:10.1196/annals.1414.032

Cited by 11 publications

(6 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (PC) is one of the most common malignancies in men in Europe and the United States . Local PC is potentially curable with radiation therapy, hormone therapy, and/or radical prostectomy . However, up to 40% of the patients who are diagnosed with localized disease ultimately develop advanced PC, even after initial treatment of local disease .…”

Section: Prostate Cancermentioning

confidence: 99%

Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin

Hasselt

Gupta

Hussein

et al. 2015

CPT Pharmacometrics Syst. Pharmacol.

View full text Add to dashboard Cite

Frameworks that associate cancer dynamic disease progression models with parametric survival models for clinical outcome have recently been proposed to support decision making in early clinical development. Here we developed such a disease progression clinical outcome model for castration-resistant prostate cancer (CRPC) using historical phase II data of the anticancer agent eribulin. Disease progression was captured using the dynamics of prostate-specific antigen (PSA). For clinical outcome, overall survival (OS) was used. The model for PSA dynamics comprised parameters for baseline PSA (23.2 ng/ml, relative standard error (RSE) 16.5%), growth rate (0.00879 day−1, RSE 12.6%), drug effect (0.241 µg·h·l−1 day−1, RSE 32.6%), and resistance development (0.0113 day−1, RSE 44.3%). OS was modeled according to a Weibull distribution. Predictors for survival included model-predicted PSA time to nadir (TTN), PSA growth rate, Eastern Cooperative Oncology Group (ECOG) score, and baseline PSA. The developed framework can be considered to support informative design and analysis of drugs developed for CRPC.

show abstract

Section: Prostate Cancermentioning

confidence: 99%

Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin

Hasselt

Gupta

Hussein

et al. 2015

CPT Pharmacometrics Syst. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…We found that a significant proportion of prostate cancers in Korean men are poorly differentiated, regardless of initial serum PSA level or clinical stage at presentation; such poorly differentiated tumors adversely affect prognosis, causing a greater rate of PSA failure [6]. Radical prostatectomy (RP) is the treatment of choice for men with localized prostate cancer [7,8]. In addition, surgeons can now anatomically dissect the prostate, thus reducing perioperative morbidity during and after RP [9].…”

Section: Introductionmentioning

confidence: 99%

Biochemical Recurrence-Free and Cancer-Specific Survival after Radical Prostatectomy at a Single Institution

et al. 2010

View full text Add to dashboard Cite

PurposeTo analyze the biochemical recurrence-free and cancer-specific survival after radical prostatectomy in a consecutive series of patients with prostate cancer.Materials and MethodsWe retrospectively reviewed data for 1,822 patients who underwent radical prostatectomy with pelvic lymph node dissection at our institution between 1990 and 2009. After excluding 498 patients who were treated with neoadjuvant androgen deprivation therapy or who were followed up for ≤6 months, we included 1324 patients (mean age, 64.4 years; mean prostate-specific antigen [PSA] level, 12.3 ng/ml). We assessed patient age at the time of surgery, preoperative PSA concentration, biopsy and pathologic Gleason scores, pathologic stage, surgical margin status, disease progression, and survival.ResultsThe mean follow-up time was 40 months (range, 6-193 months). The 5- and 10-year biochemical recurrence-free survival rates were 73.2% and 66.2%, respectively, and the 10-year cancer-specific survival rate was 92.4%. The mean time from surgery to biochemical recurrence was 18 months. In the multivariate analysis, Gleason score (4+3 vs. 2-6, p=0.004; 8-10 vs. 2-6, p<0.001), pathologic stage (pT3a vs. pT2, p=0.001; pT3b-4 vs. pT2, p<0.001; pN1 vs. pT2, p<0.001), and resection margin status (p<0.001) were statistically significant predictors of biochemical recurrence, with only pathologic stage (pT3b-4 vs. pT2, p=0.006; pN1 vs. pT2, p=0.010) being a statistically significant predictor of cancer-specific survival.ConclusionsRadical prostatectomy resulted in favorable cancer control in more than 70% of patients after 5 years and a low (<10%) cancer-specific mortality rate after 10 years. The factors predictive of biochemical recurrence were Gleason score, pathologic stage, and resection margin status.

show abstract

“…Active surveillance, brachytherapy, external beam radiation therapy (EBRT), HT, and RP are the current options for prostate cancer treatment, each with a distinct impact on a patient's health-related quality of life. For many patients with a long life expectancy, RP remains the most effective approach with respect to both oncologic success and maximization of quality of life [1, 128–130]. …”

Section: Discussionmentioning

confidence: 99%

“…Although it is a recent technological advancement, robotic surgery has shown an increasing rate of adoption worldwide. Currently, more than 30,000 patients have undergone this procedure worldwide [1]. Recent literatures have compared RRP and RALP.…”

Section: New Techniques In Rp Surgery and Rp Futurementioning

confidence: 99%

See 1 more Smart Citation

Contemporary Radical Prostatectomy

Moul

Sun

2011

Prostate Cancer

View full text Add to dashboard Cite

Purpose. Patients diagnosed with clinically localized prostate cancer have more surgical treatment options than in the past. This paper focuses on the procedures' oncological or functional outcomes and perioperative morbidities of radical retropubic prostatectomy, radical perineal prostatectomy, and robotic-assisted laparoscopic radical prostatectomy. Materials and Methods. A MEDLINE/PubMed search of the literature on radical prostatectomy and other new management options was performed. Results. Compared to the open procedures, robotic-assisted radical prostatectomy has no confirmed significant difference in most literatures besides less blood loss and blood transfusion. Nerve sparing is a safe means of preserving potency on well-selected patients undergoing radical prostatectomy. Positive surgical margin rates of radical prostatectomy affect the recurrence and survival of prostate cancer. The urinary and sexual function outcomes have been vastly improved. Neoadjuvant treatment only affects the rate of positive surgical margin. Adjuvant therapy can delay and reduce the risk of recurrence and improve the survival of the high risk prostate cancer. Conclusions. For the majority of patients with organ-confined prostate cancer, radical prostatectomy remains a most effective approach. Radical perineal prostatectomy remains a viable approach for patients with morbid obesity, prior pelvic surgery, or prior pelvic radiation. Robot-assisted laparoscopic prostatectomy (RALP) has become popular among surgeons but has not yet become the firmly established standard of care. Long-term data have confirmed the efficacy of radical retropubic prostatectomy with disease control rates and cancer-specific survival rates.

show abstract

Radical Prostatectomy

Cited by 11 publications

References 78 publications

Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin

Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin

Biochemical Recurrence-Free and Cancer-Specific Survival after Radical Prostatectomy at a Single Institution

Contemporary Radical Prostatectomy

Contact Info

Product

Resources

About